ZBIO vs IMVT vs ARDX vs RCUS vs HALO vs JPM

For growth investors, Zenas BioPharma, Inc.

(ZBIO) is the stronger pick with 100. 0% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Zenas BioPharma, Inc. (ZBIO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Halozyme Therapeutics, Inc. at 27. 1x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 37x versus JPMorgan Chase & Co. 's 0. 81x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -3. 1% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: HALO returned +701. 6% versus ZBIO's +10. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 58β versus Arcus Biosciences, Inc. 's 2. 00β — meaning RCUS is approximately 243% more volatile than HALO relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 44% for Halozyme Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zenas BioPharma, Inc.

(ZBIO) is pulling ahead at 100. 0% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: JPMorgan Chase & Co. grew EPS 1. 5% year-over-year, compared to -124. 5% for Zenas BioPharma, Inc.. Over a 3-year CAGR, ARDX leads at 98. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -37. 8% for Zenas BioPharma, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -21. 1% for ZBIO. At the gross margin level — before operating expenses — ZBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 37x versus JPMorgan Chase & Co. 's 0. 81x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 6x forward P/E versus 14. 4x for JPMorgan Chase & Co. — 5. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARDX: 198. 8% to $17. 00.

In this comparison, JPM (1.

9% yield) pays a dividend. ZBIO, IMVT, ARDX, RCUS, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, RCUS: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZBIO (Healthcare) and IMVT (Healthcare) and ARDX (Healthcare) and RCUS (Healthcare) and HALO (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZBIO is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; ARDX is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock; HALO is a small-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while ZBIO, IMVT, ARDX, RCUS, HALO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.